# A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct05923008/  
OnCo record `nct05923008` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IBI130 in advanced solid tumours, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.

## Summary

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors. ClinicalTrials.gov record last updated 2023-11-29: recruiting. Enrollment is planned at 182 participants. Primary completion is estimated at 2024-11-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: IBI130. Registered primary measures: Adverse events (AEs).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05923008
- Phase: 1/2
- Setting: A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
- Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- Enrolled: 182

## Notes

- ClinicalTrials.gov record last updated 2023-11-29: recruiting. Enrollment is planned at 182 participants. Primary completion is estimated at 2024-11-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT05923008: https://clinicaltrials.gov/study/NCT05923008

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- companies: [Innovent Biologics](https://onco.cc/companies/innovent/)
- drugs: [IBI130](https://onco.cc/drugs/ibi130/)

---
JSON: https://onco.cc/api/v1/entities/nct05923008.json